Neuren Pharmaceuticals Limited

ASX:NEU Rapporto sulle azioni

Cap. di mercato: AU$2.0b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Neuren Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Neuren Pharmaceuticals' Il CEO è Jon Pilcher, nominato in May2020, e ha un mandato di 4.25 anni. la retribuzione annua totale è A$ 1.36M, composta da 40.2% di stipendio e 59.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.31% delle azioni della società, per un valore di A$ 6.20M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.1 anni e 6.1 anni.

Informazioni chiave

Jon Pilcher

Amministratore delegato

AU$1.4m

Compenso totale

Percentuale dello stipendio del CEO40.2%
Mandato del CEO4.3yrs
Proprietà del CEO0.3%
Durata media del management4.2yrs
Durata media del Consiglio di amministrazione6.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14
Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jon Pilcher rispetto agli utili di Neuren Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

AU$117m

Mar 31 2024n/an/a

AU$137m

Dec 31 2023AU$1mAU$549k

AU$157m

Sep 30 2023n/an/a

AU$106m

Jun 30 2023n/an/a

AU$55m

Mar 31 2023n/an/a

AU$28m

Dec 31 2022AU$546kAU$396k

AU$184k

Sep 30 2022n/an/a

-AU$3m

Jun 30 2022n/an/a

-AU$7m

Mar 31 2022n/an/a

-AU$7m

Dec 31 2021AU$432kAU$203k

-AU$8m

Compensazione vs Mercato: La retribuzione totale di Jon ($USD 929.24K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 1.59M ).

Compensazione vs guadagni: La retribuzione di Jon è aumentata di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Jon Pilcher

4.3yrs

Mandato

AU$1,364,404

Compensazione

Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Jonathan Pilcher
CEO, MD & Executive Director4.3yrsAU$1.36m0.31%
A$ 6.1m
Lauren Frazer
CFO & Company Secretary4.1yrsNessun datoNessun dato
Lawrence Glass
Chief Science Officer20.7yrsNessun datoNessun dato
Gerry Zhao
Vice President of Corporate Developmentno dataNessun datoNessun dato
Liza Squires
Chief Medical Officer2.2yrsNessun datoNessun dato

4.2yrs

Durata media

Gestione esperta: Il team dirigenziale di NEU è considerato esperto (durata media dell'incarico 4.1 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Jonathan Pilcher
CEO, MD & Executive Director3.3yrsAU$1.36m0.31%
A$ 6.1m
Dianne Angus
Independent Non-Executive Director6.2yrsAU$75.00k0.023%
A$ 458.1k
Jenny Harry
Independent Non-Executive Director6.2yrsAU$75.00k0.023%
A$ 453.0k
Patrick Donald Davies
Independent Non-Executive Chairman6.2yrsAU$125.00k0.21%
A$ 4.0m
Joe Basile
Independent Non-Executive Director1.5yrsAU$62.50k0.017%
A$ 326.9k

6.2yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NEU sono considerati esperti (durata media dell'incarico 6.1 anni).